Overview

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Summary

In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.

Phase:

Phase 2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborators:

Cephalon
Millennium Pharmaceuticals, Inc.

Treatments:

BB 1101
Bendamustine Hydrochloride
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate